Futura Medical Reports Positive Trial Results for Upgraded Eroxon Intense Gel

Futura Medical PLC has announced successful results from a four-week home user trial for its new Eroxon Intense formulation, designed to treat erectile dysfunction. The study, which involved 223 participants, demonstrated high efficacy rates in effectively managing mild to moderate cases. According to the clinical data, the upgraded formula showed significantly stronger early effects compared to the company's existing product currently on the market. These positive outcomes are expected to bolster the company's consumer healthcare portfolio and strengthen its competitive global position. As a key product milestone, these results serve as a bullish catalyst for the company's stock performance on the AIM market. Futura Medical aims to provide faster and more effective solutions for users through this innovation, further validating its long-term growth strategy.

Fontes:proactiveinvestors.co.ukinvestegate.co.uktipranks.commarketbeat.comfuturamedical.comreuters.combloomberg.comfinance.yahoo.cominvesting.com